1、novotech-12 December 2024Triple Negative Breast Cancer -Global Clinical Trial Landscape(2024)Marketed drugs such as Immune checkpoint inhibitors(e.g.,Keytru-da)and antibody-drug conjugates(e.g.,Trodelvy)are vital in targeting TNBC pathwaysPhase III trials focus on innovative ADCs(e.g.,datopotamab de

2、ruxte-can)and immune ther-apies(e.g.,adagloxad simolenin),driving progress in TNBC treatmentThe Asia-Pacific region shows faster recruitment rates than the United StatesTriple Negative Breast CancerTRIAL CONTRIBUTIONSTNBC is a highly aggressive and heteroge-neous subtype,comprising 10-15%of global b

3、reast cancer casesThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permi

4、ssion of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reprodu

5、ction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-#DYK Did youknow?In the Asia-Pacific region,China reported an estimated higher incidence of TNBC case

6、sIn Europe,Germany reported an estimated higher incidence of TNBCThe United States had the highest estimat-ed number of TNBC cases in North AmericaIn ROW,Brazil reported the highest incidence of TNBCTRIPLE NEGATIVE BREAST CANCER(TNBC)GLOBAL CLINICAL TRIAL LANDSCAPE(2024)0.3MESTIMATEDTNBC CASES 55%NO